Promoter Alterations in Glioblastoma: A Systematic Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 3

PMID 33800183

Citations 36

Authors

Nathalie Olympios

Vianney Gilard

Florent Marguet

Florian Clatot

Frederic Di Fiore

Maxime Fontanilles

Affiliations

Soon will be listed here.

Abstract

Glioblastoma, the most frequent and aggressive primary malignant tumor, often presents with alterations in the telomerase reverse transcriptase promoter. Telomerase is responsible for the maintenance of telomere length to avoid cell death. Telomere lengthening is required for cancer cell survival and has led to the investigation of telomerase activity as a potential mechanism that enables cancer growth. The aim of this systematic review is to provide an overview of the available data concerning alterations and glioblastoma in terms of incidence, physiopathological understanding, and potential therapeutic implications.

Citing Articles

Chemoradiation treatment with or without concurrent tumor-treating fields (TTFields) therapy in newly diagnosed glioblastoma (GBM) patients in China.

Liang L, Chen L, Ni C, Shi W, Zhou Z, Chen S Chin Neurosurg J. 2025; 11(1):5.

PMID: 40055813 PMC: 11887109. DOI: 10.1186/s41016-025-00391-w.

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.

PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.

TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real-World Study.

Xing H, Liu D, Li J, Ge Y, Guo X, Chen W Cancer Med. 2025; 14(2):e70533.

PMID: 39804195 PMC: 11727134. DOI: 10.1002/cam4.70533.

Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging.

Gough R, Treffy R, Krucoff M, Desai R Cancers (Basel). 2025; 17(1.

PMID: 39796751 PMC: 11720166. DOI: 10.3390/cancers17010124.

Predictive and Prognostic Significance of Molecular Biomarkers in Glioblastoma.

Shah S, Nag A, Sachithanandam S, Lucke-Wold B Biomedicines. 2025; 12(12.

PMID: 39767571 PMC: 11727522. DOI: 10.3390/biomedicines12122664.

References

Yamashita K, Hatae R, Hiwatashi A, Togao O, Kikuchi K, Momosaka D . Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma. Diagn Interv Imaging. 2019; 100(7-8):411-419. DOI: 10.1016/j.diii.2019.02.010. View

Mayr L, Guntner A, Madlener S, Schmook M, Peyrl A, Azizi A . Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated -Fusion Positive Pediatric High-Grade Glioma. J Pers Med. 2020; 10(4). PMC: 7766483. DOI: 10.3390/jpm10040290. View

Huang F, Hodis E, Xu M, Kryukov G, Chin L, Garraway L . Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339(6122):957-9. PMC: 4423787. DOI: 10.1126/science.1229259. View

Geng P, Zhao X, Ou J, Li J, Sa R, Liang H . TERT Genetic Mutations as Prognostic Marker in Glioma. Mol Neurobiol. 2016; 54(5):3665-3669. DOI: 10.1007/s12035-016-9930-2. View

Yao Y, Wang X, Jin K, Zhu J, Wang Y, Xiong S . B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. J Neurooncol. 2008; 89(2):121-9. DOI: 10.1007/s11060-008-9601-x. View

Abou-El-Ardat K, Seifert M, Becker K, Eisenreich S, Lehmann M, Hackmann K . Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas. Neuro Oncol. 2017; 19(4):546-557. PMC: 5464316. DOI: 10.1093/neuonc/now231. View

Fontanilles M, Marguet F, Beaussire L, Magne N, Pepin L, Alexandru C . Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma. Acta Neuropathol Commun. 2020; 8(1):179. PMC: 7641818. DOI: 10.1186/s40478-020-01057-7. View

Adotevi O, Dosset M, Galaine J, Beziaud L, Godet Y, Borg C . Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. Hum Vaccin Immunother. 2013; 9(5):1073-7. PMC: 3899142. DOI: 10.4161/hv.23587. View

Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B . Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol. 2016; 18(8):1099-108. PMC: 4933482. DOI: 10.1093/neuonc/now021. View

10.

Reis R, Lopes J, Kleihues P, Ohgaki H . Genetic profile of gliosarcomas. Am J Pathol. 2000; 156(2):425-32. PMC: 1850048. DOI: 10.1016/S0002-9440(10)64746-3. View

11.

Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M . TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2014; 17(1):45-52. PMC: 4483052. DOI: 10.1093/neuonc/nou158. View

12.

Brito C, Azevedo A, Esteves S, Marques A, Martins C, Costa I . Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. BMC Cancer. 2019; 19(1):968. PMC: 6798410. DOI: 10.1186/s12885-019-6177-0. View

13.

Zacher A, Kaulich K, Stepanow S, Wolter M, Kohrer K, Felsberg J . Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel. Brain Pathol. 2016; 27(2):146-159. PMC: 8029406. DOI: 10.1111/bpa.12367. View

14.

Korber V, Yang J, Barah P, Wu Y, Stichel D, Gu Z . Evolutionary Trajectories of IDH Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. Cancer Cell. 2019; 35(4):692-704.e12. DOI: 10.1016/j.ccell.2019.02.007. View

15.

Shu C, Wang Q, Yan X, Wang J . The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival. Cancer Med. 2018; 7(8):3704-3712. PMC: 6089138. DOI: 10.1002/cam4.1666. View

16.

Broniscer A, Tatevossian R, Sabin N, Klimo Jr P, Dalton J, Lee R . Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol. 2013; 40(3):327-36. PMC: 4042629. DOI: 10.1111/nan.12093. View

17.

Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones D . Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013; 126(6):907-15. DOI: 10.1007/s00401-013-1195-5. View

18.

Wu G, Diaz A, Paugh B, Rankin S, Ju B, Li Y . The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014; 46(5):444-450. PMC: 4056452. DOI: 10.1038/ng.2938. View

19.

Horn S, Figl A, Rachakonda P, Fischer C, Sucker A, Gast A . TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339(6122):959-61. DOI: 10.1126/science.1230062. View

20.

Law M, Lower K, Voon H, Hughes J, Garrick D, Viprakasit V . ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell. 2010; 143(3):367-78. DOI: 10.1016/j.cell.2010.09.023. View